Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.